Routine vs selective invasive strategies in patients with acute coronary syndromes - A collaborative meta-analysis of randomized trials

被引:592
作者
Mehta, SR
Cannon, CP
Fox, KAA
Wallentin, L
Boden, WE
Spacek, R
Widimsky, P
McCullough, PA
Hunt, D
Braunwald, E
Yusuf, S
机构
[1] McMaster Univ, Dept Med, Hamilton, ON L6K 1B8, Canada
[2] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] William Beaumont Hosp, Royal Oak, MI 48072 USA
[5] Charles Univ, Sch Med 3, Cardioctr, Univ Hosp Kralovske Vinohrady, Prague, Czech Republic
[6] Hartford Hosp, Div Cardiol, Hartford, CT 06115 USA
[7] Hartford Hosp, Henry Low Heart Ctr, Hartford, CT 06115 USA
[8] Univ Uppsala Hosp, Uppsala Clin Res Ctr, Uppsala, Sweden
[9] Royal Infirm, Dept Med, Edinburgh, Midlothian, Scotland
[10] Harvard Univ, Sch Med, Boston, MA USA
[11] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[12] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2005年 / 293卷 / 23期
关键词
D O I
10.1001/jama.293.23.2908
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) can be cared for with a routine invasive strategy involving coronary angiography and revascularization or more conservatively with a selective invasive strategy in which only those with recurrent or inducible ischemia are referred for acute intervention. Objective To conduct a meta-analysis that compares benefits and risks of routine invasive vs selective invasive strategies. Data Sources Randomized controlled trials identified through search of MEDLINE and the Cochrane databases (1970 through June 2004) and hand searching of cross-references from original articles and reviews. Study Selection Trials were included that involved patients with unstable angina or NSTEMI who received a routine invasive or a selective invasive strategy. Data Extraction Major outcomes of death and myocardial infarction (MI) occurring from initial hospitalization to the end of follow-up were extracted from published results of eligible trials. Data Synthesis A total of 7 trials (N = 9212 patients) were eligible. Overall, death or MI was reduced from 663 (14.4%) of 4604 patients in the selective invasive group to 561 (12.2%) of 4608 patients in the routine invasive group (odds ratio [OR], 0.82; 95% confidence interval [Cl], 0.72-0.93; P=.001). There was a nonsignificant trend toward fewer deaths (6.0% vs 5.5%; OR, 0.92; 95% Cl, 0.77-1.09; P=.33) and a significant reduction in MI alone (9.4% vs 7.3%; OR, 0.75; 95% CI, 0.65-0.88; P<.001). Higher-risk patients with elevated cardiac biomarker levels at baseline benefited more from routine intervention, with no significant benefit observed in lower-risk patients with negative baseline marker levels. During the initial hospitalization, a routine invasive strategy was associated with a significantly higher early mortality (1.1% vs 1.8% for selective vs routine, respectively; OR, 1.60; 95% Cl, 1.14-2.25; P=.007) and the composite of death or MI (3.8% vs 5.2%; OR, 1.36; 95% CI, 1.12-1.66; P = .002). But after discharge, the routine invasive strategy was associated with fewer subsequent deaths (4.9% vs 3.8%; OR, 0.76; 95% Cl, 0.62-0.94; P = .01) and the composite of death or MI (11.0% vs 7.4%; OR, 0.64; 95% CI, 0.56-0.75; P<.001). At the end of follow-up, there was a 33% reduction in severe angina (14.0% vs 11.2%; OR, 0.77; 95% CI, 0.68-0.87; P<.001) and a 34% reduction in rehospitalization (41.3% vs 32.5%; OR, 0.66; 95% CI, 0.60-0.72; P<.001) with a routine invasive strategy. Conclusions A routine invasive strategy exceeded a selective invasive strategy in reducing MI, severe angina, and rehospitalization over a mean follow-up of 17 months. But routine intervention was associated with a higher early mortality hazard and a trend toward a mortality reduction at follow-up. Future strategies should explore ways to minimize the early hazard and enhance later benefits by focusing on higher-risk patients and optimizing timing of intervention and use of proven therapies.
引用
收藏
页码:2908 / 2917
页数:10
相关论文
共 39 条
  • [21] MANTEL N, 1959, J NATL CANCER I, V22, P719
  • [22] A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy - Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial
    McCullough, PA
    O'Neill, WW
    Graham, M
    Stomel, RJ
    Rogers, F
    David, S
    Farhat, A
    Kazlauskaite, R
    Al-Zagoum, M
    Grines, CL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) : 596 - 605
  • [23] Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
    Mehta, SR
    Yusuf, S
    Peters, RJG
    Bertrand, ME
    Lewis, BS
    Natarajan, MK
    Maimberg, K
    Rupprecht, HJ
    Zhao, F
    Chrolavicius, S
    Copland, I
    Fox, KAA
    [J]. LANCET, 2001, 358 (9281) : 527 - 533
  • [24] Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery - Invasive versus conservative strategy (TRUCS Study)
    Michalis, LK
    Stroumbis, CS
    Pappas, K
    Sourla, E
    Niokou, D
    Goudevenos, JA
    Siogas, C
    Sideris, DA
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (23) : 1954 - 1959
  • [25] Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction - Results from a randomized trial
    Morrow, DA
    Cannon, CP
    Rifai, N
    Frey, MJ
    Vicari, R
    Lakkis, N
    Robertson, DH
    Hille, DA
    DeLucca, PT
    DiBattiste, PM
    Demopoulos, LA
    Weintraub, WS
    Braunwald, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (19): : 2405 - 2412
  • [26] Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes -: A randomized controlled trial
    Neumann, FJ
    Kastrati, A
    Pogatsa-Murray, G
    Mehilli, J
    Bollwein, H
    Bestehorn, HP
    Schmitt, C
    Seyfarth, M
    Dirschinger, J
    Schömig, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (12): : 1593 - 1599
  • [27] Russell RO., 1978, AM J CARDIOL, V42, P839
  • [28] SCOTT SM, 1994, CIRCULATION, V90, P120
  • [29] Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction:: An open multicenter randomized trial -: The VINO study
    Spacek, R
    Widimsky, P
    Straka, Z
    Jiresová, E
    Dvorák, J
    Polásek, R
    Karel, I
    Jirmár, R
    Lisa, L
    Budesínsky, T
    Málek, F
    Stanka, P
    [J]. EUROPEAN HEART JOURNAL, 2002, 23 (03) : 230 - 238
  • [30] Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial
    Steinhubl, SR
    Berger, PB
    Mann, JT
    Fry, ETA
    DeLago, A
    Wilmer, C
    Topol, EJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (19): : 2411 - 2420